Tricida, Inc. (NASDAQ:TCDA) Short Interest Update

Tricida, Inc. (NASDAQ:TCDAGet Rating) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 4,300,000 shares, an increase of 25.0% from the March 31st total of 3,440,000 shares. Based on an average daily volume of 385,100 shares, the days-to-cover ratio is presently 11.2 days. Currently, 16.2% of the company’s stock are short sold.

TCDA stock opened at $8.97 on Tuesday. The company has a quick ratio of 4.94, a current ratio of 4.94 and a debt-to-equity ratio of 584.92. The business has a 50 day moving average price of $9.04 and a two-hundred day moving average price of $8.40. The company has a market cap of $497.05 million, a price-to-earnings ratio of -2.61 and a beta of 1.10. Tricida has a twelve month low of $3.55 and a twelve month high of $12.45.

Tricida (NASDAQ:TCDAGet Rating) last posted its quarterly earnings results on Tuesday, March 29th. The company reported ($0.92) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.21). During the same quarter in the previous year, the company posted ($1.09) earnings per share. On average, equities research analysts anticipate that Tricida will post -2.35 EPS for the current fiscal year.

A number of equities research analysts recently issued reports on TCDA shares. The Goldman Sachs Group started coverage on Tricida in a research report on Tuesday, April 12th. They issued a “buy” rating and a $25.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $18.00 target price (down previously from $20.00) on shares of Tricida in a research report on Wednesday, March 30th. Finally, Zacks Investment Research lowered Tricida from a “buy” rating to a “hold” rating in a research report on Thursday, January 20th.

In other news, major shareholder Brian M. Isern sold 11,804 shares of the firm’s stock in a transaction dated Thursday, April 28th. The stock was sold at an average price of $10.61, for a total transaction of $125,240.44. Following the sale, the insider now owns 770,496 shares of the company’s stock, valued at $8,174,962.56. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 47.40% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Tricida by 92.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,270 shares of the company’s stock valued at $27,000 after purchasing an additional 1,569 shares in the last quarter. Dorsey Wright & Associates bought a new position in Tricida in the first quarter valued at approximately $30,000. Hsbc Holdings PLC bought a new position in shares of Tricida during the 3rd quarter worth approximately $47,000. Barclays PLC boosted its stake in shares of Tricida by 112.7% during the 3rd quarter. Barclays PLC now owns 20,253 shares of the company’s stock worth $94,000 after acquiring an additional 10,733 shares during the period. Finally, BlackRock Inc. boosted its stake in shares of Tricida by 1.2% during the 4th quarter. BlackRock Inc. now owns 960,777 shares of the company’s stock worth $9,185,000 after acquiring an additional 11,169 shares during the period. Hedge funds and other institutional investors own 79.28% of the company’s stock.

About Tricida (Get Rating)

Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.

Featured Articles

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with's FREE daily email newsletter.